Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
Kudo M, Ueshima K, Yokosuka O, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Akazawa K, Yoshimura KI, Johnson P, Arai Y; SILIUS study group. Kudo M, et al. Among authors: yoshimura ki. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7. Lancet Gastroenterol Hepatol. 2018. PMID: 29631810 Clinical Trial.
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
Kanai M, Yoshimura K, Tsumura T, Asada M, Suzuki C, Niimi M, Matsumoto S, Nishimura T, Nitta T, Yasuchika K, Taura K, Mori Y, Hamada A, Inoue N, Tada S, Yanagihara K, Yazumi S, Osaki Y, Chiba T, Ikai I, Fukushima M, Uemoto S, Hatano E. Kanai M, et al. Cancer Chemother Pharmacol. 2011 Jun;67(6):1429-34. doi: 10.1007/s00280-010-1443-5. Epub 2010 Sep 2. Cancer Chemother Pharmacol. 2011. PMID: 20811895 Free article. Clinical Trial.
Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.
Nagayama S, Hasegawa S, Hida K, Kawada K, Hatano E, Nakamura K, Seo S, Taura K, Yasuchika K, Matsuo T, Zaima M, Kanazawa A, Terajima H, Tada M, Adachi Y, Nishitai R, Manaka D, Yoshimura T, Doi K, Horimatsu T, Mitsuyoshi A, Yoshimura K, Niimi M, Matsumoto S, Sakai Y, Uemoto S. Nagayama S, et al. Int J Clin Oncol. 2017 Apr;22(2):316-323. doi: 10.1007/s10147-016-1050-5. Epub 2016 Oct 17. Int J Clin Oncol. 2017. PMID: 27752787 Clinical Trial.
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I. Miura Y, et al. Gastric Cancer. 2018 Jan;21(1):84-95. doi: 10.1007/s10120-017-0725-6. Epub 2017 May 11. Gastric Cancer. 2018. PMID: 28497176 Clinical Trial.
A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
Akiyoshi K, Hamaguchi T, Yoshimura K, Takahashi N, Honma Y, Iwasa S, Takashima A, Kato K, Yamada Y, Onodera H, Takeshita S, Yasui H, Sakai G, Akatsuka S, Ogawa K, Horita Y, Nagai Y, Shimada Y. Akiyoshi K, et al. Clin Colorectal Cancer. 2018 Mar;17(1):e83-e89. doi: 10.1016/j.clcc.2017.10.004. Epub 2017 Oct 16. Clin Colorectal Cancer. 2018. PMID: 29169974 Clinical Trial.
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.
Ikeda S, Yoshioka H, Kaneda T, Yokoyama T, Niwa T, Sone N, Ishida T, Morita M, Tomioka H, Komaki C, Hirabayashi M, Hasegawa Y, Noguchi T, Nakano Y, Sakaguchi C, Yoshimura K, Hirai T. Ikeda S, et al. Oncology. 2019;97(6):327-333. doi: 10.1159/000501967. Epub 2019 Aug 14. Oncology. 2019. PMID: 31412347 Clinical Trial.
A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Yokoyama T, Yoshioka H, Fujimoto D, Demura Y, Hirano K, Kawai T, Kagami R, Washio Y, Ishida T, Kogo M, Tomii K, Okuno T, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim YH, Miyakoshi C, Yoshimura K, Hirai T; Kyoto Thoracic Oncology Research Group (KTORG). Yokoyama T, et al. Lung Cancer. 2019 Sep;135:175-180. doi: 10.1016/j.lungcan.2019.03.030. Epub 2019 Mar 28. Lung Cancer. 2019. PMID: 31446992 Clinical Trial.
191 results